Pitolisant Hydrochloride (Wakix)

Multiple Targeting Approaches on Histamine H3 Receptor Antagonists

With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased. Since histamine H3 receptor antagonists in clinical development have been tested for a variety of different indications, the combination of pharmacological properties in one molecule for improved pharmacological effe...

Update on the treatment of narcolepsy: clinical efficacy of pitolisant

Narcolepsy is a neurological disease that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness (EDS). In 60-70% of individuals with narcolepsy, it is also characterized by cataplexy or a sudden loss of muscle tone that is triggered by positive or negative emotions. Narcolepsy decreases the quality of life of the afflicted individuals. Currently used drugs treat ED...

The histamine H₃-receptor inverse agonist pitolisant improves fear memory in mice.

Numerous studies have demonstrated that brain histamine plays a crucial role in learning and memory and histamine H3 receptor inverse agonists (H3R inverse agonists) have been proposed to treat cognitive disorders. Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) was the first H3R inverse agonist that has been tested in human trials and is well tolerated. T...

Acrescent, INN- memantine hydrochloride / donepezil hydrochloride

Urea Hydrochloride

Sir,?In reply to Capt. T. D. W. Gillespie's inquiry in the Novtmber issue of the I. M. Q. as to the quantity of quinine urea hydrochloride to be injected hypodermically to produce local anaesthesia, I may say as follows: In the New York Medical Journal (1915, II, 708) Amster recommends quin-urea hydro as a local anaesthetic. He has performed 200 severe operations with a freshly prepared solutio...